BioCentury on BioBusiness,
Emerging Company Profile
Tansna developing non-sedating propofol analogs for refractory epilepsy
Related tables, figures and sidebars
Tansna: Quieting convulsions
Monday, September 16, 2013
Propofol is used off-label in hospitals to treat uncontrolled
seizures, but its potent sedative properties preclude everyday use. Tansna
Therapeutics Inc. is developing non-sedating analogs of propofol
that could help treat the one-third of epilepsy patients who are refractory to
marketed maintenance therapies.
Scientific founder Max Baker, associate professor in the
Department of Anesthesia at the University
of Iowa, was actually looking for a sedative with faster recovery. But
his MB003, a para-substituted analog of propofol, turned out to be a poor
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2014 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
If you are a current subscriber, log in below or in the upper right corner of this
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]